Table 1: Dataset Composition and Coverage

Component	N (%)	Data Type	Coverage
Total Participants	18,205 (100.0%)	Combined dataset	Johannesburg, SA
Clinical Trial Participants	9,103 (50.0%)	Biomarkers + DemographicsFacility-based	
Survey Participants	9,102 (49.97%)	Socioeconomic + Demograp6iosnmunity-based	
	Biomarker Data Availabilit	ry (Clinical Cohort)	
CD4 cell count	1,283 (14.1%)	cells/µL	HIV studies
Fasting glucose	2,731 (30.0%)	mg/dL	Metabolic studies
Blood pressure	4,957 (54.5%)	mmHg (systolic/diastolic)	All clinical trials
Cholesterol panel	2,502 (27.5%)	mg/dL (LDL/HDL/Total)	Metabolic studies
Hemoglobin	1,282 (14.1%)	g/dL	HIV/TB studies
Creatinine	1,251 (13.7%)	mg/dL	Renal function
Any biomarker data	6,244 (68.6%)	Multiple measures	Clinical subset
	Spatial Cove	erage	
Participants with coordinates	18,205 (100.0%)	Latitude/longitude	GPS precision
Participants with ward info	9,102 (50.0%)	Administrative boundaries	Survey cohort only
Unique wards covered	55 wards	City of Johannesburg	Urban coverage
	Temporal Cov	verage	
Study period	2002-2021	19 years	All seasons
Climate lag windows	0-21 days	Daily temperature	ECMWF ERA5
	Study Type Dis	tribution	
HIV treatment trials	5,847 (32.1%)	Randomized controlled	Facility-based
Metabolic studies	3,256 (17.9%)	Cross-sectional	Clinic recruitment

Notes:

- Clinical trial data includes biomarkers but limited socioeconomic variables
 Survey data includes comprehensive socioeconomic data but no biomarkers
 All participants have climate exposure data matched by coordinates and date
 Temperature data from ECMWF ERA5 reanalysis with 0.25° spatial resolution